试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-26
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
编号:NCT04373044登记状态:提前终止企业 / 申办者:University of Southern California
药物 / 成分:Baricitinib、Hydroxychloroquine、Placebo Administration
登记的停止原因(原文):The study was terminated after the release of results of ACTT-2 (NCT04401579).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-25
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
编号:NCT00452478登记状态:提前终止企业 / 申办者:Shire
药物 / 成分:Lanthanum carbonate
登记的停止原因(原文):This study was stopped by the sponsor based on a non-safety related corporate decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-25
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
编号:NCT01220128登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A、Placebo、Aromatase inhibitor、5-Fluorouracil
登记的停止原因(原文):Study termination due to negative Ph III of another study product from same technology platform.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-25
Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease
编号:NCT01987908登记状态:提前终止企业 / 申办者:Baxalta now part of Shire
药物 / 成分:Aes-103、Placebo
登记的停止原因(原文):Study was terminated early by the Sponsor due to unblinding between study drug and placebo groups at the subject, site and Sponsor levels.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
编号:NCT02448810登记状态:提前终止企业 / 申办者:Baxalta now part of Shire
药物 / 成分:BAX69 + infusional 5-FU/LV、BAX69 + panitumumab、BAX69 + 5-FU/LV、BAX69 + panitumumab
登记的停止原因(原文):Based on overall benefit-risk assessment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-25
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
编号:NCT03716570登记状态:提前终止企业 / 申办者:Biogen
药物 / 成分:BIIB054、Placebo
登记的停止原因(原文):Affiliated study NCT03318523 did not meet its primary outcome measure of change from baseline measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and did not demonstrate efficacy on secondary outcome measures
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-25
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study
编号:NCT03783754登记状态:提前终止企业 / 申办者:The George Institute
药物 / 成分:telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg、Placebo oral capsule
登记的停止原因(原文):Not feasible to continue
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-24
Early Prophylaxis Immunologic Challenge (EPIC) Study
编号:NCT01376700登记状态:提前终止企业 / 申办者:Baxalta now part of Shire
药物 / 成分:Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
登记的停止原因(原文):It became unlikely to achieve the study objective of 50% reduction over published inhibitor rates. The Data Monitoring Committee supported this decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-24
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
编号:NCT02669264登记状态:提前终止企业 / 申办者:ADC Therapeutics S.A.
药物 / 成分:ADCT-402
登记的停止原因(原文):The study was early terminated prior to part 2 because of slow accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-05-24
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
编号:NCT03983395登记状态:提前终止企业 / 申办者:Ichnos Sciences SA
药物 / 成分:ISB 1302 250 ng/kg、ISB 1302 325 ng/kg、ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22、ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22
登记的停止原因(原文):The study was terminated during Part 1 (dose escalation), and Part 2 (expansion) of the study was not initiated. This study was voluntarily terminated due to a business decision not to proceed with the ISB 1302 asset, and not due to any safety issue.
查看官方原始记录 ↗